Mission Statement
At Erie, we develop innovative biological sensors with the potential to revolutionize the healthcare system as we know it now. Over the past 30 years, biomedical sensors have proven crucial in enhancing healthcare delivery (Tat et al., 2021). Erie maintains year-round first and second-shift personnel to respond quickly to market demands for biomedical sensors manufactured in the United States. By creating a new benchmark for biomedical sensors, we hope to give technologically sophisticated, consistent sensing to each tech-savvy customer. At Erie, we strive to convert biomedical sensors into digital and wireless market and health solutions that are both clinically and financially viable. Our goal is to pave the way for a groundbreaking platform technology that can fully integrate with universal health care.
Vision Statement
We are a high-tech industry broad differentiator, with offices throughout the United States and a focus on the growing medical sensing niche. Our broad differentiator strategy appeals to the needs of our diverse clientele, comprising medical facilities across the county, who seek avant-garde products. We utilize several transduction mechanisms, including electrochemical, optical, and acoustic, while developing biosensors. To guarantee the best possible sensing performance, we regularly incorporate innovations in bio-inspired, stretchy, translucent, greatly triboelectric materials. Our sensing devices are self-sufficient in power, inexpensive, biocompatible, and flexible, making them ideal for use in medical settings. As a result, we collaborate with medical professionals all around the United States to expand the use of ubiquitous biomedical sensors.
Financing
Our primary means of financing our investments will be the sale of stock and retained earnings, with bond issues serving as a backup plan. To ensure that our outlays never exceed our receipts, we shall perform periodic reviews of our finances. To ensure our company’s continued growth and prosperity, we will actively pursue new sources of revenue and make necessary investments. Our initial dividend policy will be $1, with future increases dependent on sales and cash flow. We want to issue shorter-term debt to avoid making larger interest payments and having a debt load. We plan to maintain a leverage ratio (assets versus equity) of 2.0 to 2.2 at all times. With any variation directly resulting from stock-outs and Big Al situations in earlier rounds, our monetary aim is 5% of sales. The AR/AP policy is expected to remain stable for roughly 30 days
Reference
Tat, T., Libanori, A., Au, C., Yau, A., & Chen, J. (2021). Advances in triboelectric nanogenerators for biomedical sensing. Biosensors and Bioelectronics, 171, 112714. Web.